The multifaceted role of AdipoRon, an adiponectin receptor agonist : tackling myosteatosis, sarcopenia and aging
(2024)
Files
ManuscrittheseCamilleSelvais.pdf
Open Access - Adobe PDF
- 12.91 MB
Details
- Authors
- Supervisors
- Brichard, Sonia
- Abstract
- Adiponectin (ApN) is a beneficial adipokine that may protect against age-related diseases and increase longevity. ApN exerts insulin-sensitizing, fat-burning and anti-inflammatory properties on the skeletal muscle. This work explores the effects of an ApN receptors’ agonist, AdipoRon, during ageing, with particular emphasis on muscle. First, we demonstrated that long-term treatment with AdipoRon slows down muscle dysfunction, myosteatosis and the development of degenerative muscle markers in middle‐aged obese mice. Second, we showed that a shorter treatment in much older mice counteracts sarcopenia, the age-related loss of muscle mass, quality and function. In both cases, the protective effects of AdipoRon were mediated through improving mitochondrial function, lipid oxidation, and autophagy, notably via the AMPK pathway. This thesis highlights ApN receptors’ agonists as promising candidates to counteract age-related decline of skeletal muscle function and potentially extend healthspan.
- Affiliations
Citations
Selvais, C. (2024). The multifaceted role of AdipoRon, an adiponectin receptor agonist : tackling myosteatosis, sarcopenia and aging. https://hdl.handle.net/2078.5/271983